Vai al contenuto principale
Coronavirus: aggiornamenti per la comunità universitaria / Coronavirus: updates for UniTo Community
Oggetto:

21-22 Translational medicine in severe asthma

Oggetto:

21-22 Translational medicine in severe asthma

Oggetto:

Anno accademico 2021/2022

Docente
Prof. Fabio Luigi Massimo Ricciardolo (Titolare del corso)
Periodo
Da definire
Tipologia
FAD
Crediti/Valenza
1
Erogazione
A distanza
Lingua
Inglese
Oggetto:

Sommario insegnamento

Oggetto:

Obiettivi formativi

Bronchial asthma is a complex and heterogeneous chronic inflammatory disorder of the airways with variable airflow obstruction. According to the Global Burden Disease Study, about 240 million people suffer from asthma worldwide, and in 2016 it caused 495.000 deaths. A subset of asthmatic patients (10-20%) has uncontrolled respiratory symptoms, with half of them being affected by severe asthma. Based on ATS/ERS expert panel consensus, severe asthma is defined as asthma requiring treatment with guideline suggested medications for GINA steps 4–5 asthma (high dose inhaled corticosteroid and long-acting beta-agonist or leukotriene modifier/theophylline) for the previous year or systemic corticosteroid for ≥50% of the previous year to maintain disease control. Severe asthma, despite affecting only 5-10% of asthmatics, is responsible for a large part of asthmarelated national healthcare costs. 

Despite a growing number of personalized therapeutic options are becoming available for severe asthmatic patients some of them still remain unresponsive or with partly controlled disease. This is in part a consequence of the great heterogeneity of the disorder, to such a degree that it is possible to identify several clinical, biological and pathophysiological phenotypes each of them underlined by specific molecular mechanisms (endotypes), which are responsible of a highly variable response of patients to therapies. Over the last years, several studies on large cohorts were performed to identify phenotype clusters, with the aim of developing personalized therapies. 

This course is focused on the description of the complexity and heterogeneity of this respiratory disorder, aiming to innovation and personalized therapy based on the principles of precision medicine.

Oggetto:

Programma

  • Definition 
  • Diagnosis
  • Pathophysiology
  • Phenotypes
  • Endotypes
  • Pharmacological Therapy and Biologics
Oggetto:

Modalità di insegnamento

Slides with power-point presentation, reviews and original articles (suggested readings).

At least 2 lessons (2 hours per lesson) and 2 meetings with students showing presentations concerning other model of precision medicine with personalized therapy (e.g. lung cancer and others).

Oggetto:

Modalità di verifica dell'apprendimento

Final test examinations

Testi consigliati e bibliografia

Oggetto:

.



Oggetto:

Note

  • 1 Luglio 2022  da ore 15 a ore 18 (eterogeneità e stratificazione);
  • 9 settembre 2022  da ore 16 a ore 18 (fenotipi e terapia personalizzata).

 

Registrazione
  • Chiusa
    Apertura registrazione
    11/04/2022 alle ore 17:00
    Chiusura registrazione
    27/06/2022 alle ore 12:00
    Oggetto:
    Ultimo aggiornamento: 11/04/2022 16:48